Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein

Bruno Sainz Jr. a,∗, Eric C. Mossel b,1, William R. Gallaher c, William C. Wimley d, C.J. Peters b, e, Russell B. Wilson f, Robert F. Garry a

a Department of Microbiology and Immunology, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
b Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA
c Department of Microbiology, Immunology and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
d Department of Biochemistry, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
e Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA
f Autoimmune Technologies, LLC, New Orleans, LA 70112, USA

Received 20 July 2005; received in revised form 9 February 2006; accepted 1 March 2006
Available online 17 April 2006

Abstract

Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) is the cause of an atypical pneumonia that affected Asia, North America and Europe in 2002–2003. The viral spike (S) glycoprotein is responsible for mediating receptor binding and membrane fusion. Recent studies have proposed that the carboxyl terminal portion (S2 subunit) of the S protein is a class I viral fusion protein. The Wimley and White interfacial hydrophobicity scale was used to identify regions within the CoV S2 subunit that may preferentially associate with lipid membranes with the premise that peptides analogous to these regions may function as inhibitors of viral infectivity. Five regions of high interfacial hydrophobicity spanning the length of the S2 subunit of SARS-CoV and murine hepatitis virus (MHV) were identified. Peptides analogous to regions of the N-terminus or the pre-transmembrane domain of the S2 subunit inhibited SARS-CoV plaque formation by 40–70% at concentrations of 15–30 μM. Interestingly, peptides analogous to the SARS-CoV or MHV loop region inhibited viral plaque formation by >80% at similar concentrations. The observed effects were dose-dependent (IC50 values of 2–4 μM) and not a result of peptide-mediated cell cytotoxicity. The antiviral activity of the CoV peptides tested provides an attractive basis for the development of new fusion peptide inhibitors corresponding to regions outside the fusion protein heptad repeat regions.

© 2006 Elsevier B.V. All rights reserved.

Keywords: Severe acute respiratory syndrome-associated coronavirus; Class I viral fusion protein; Peptide inhibitor; Murine hepatitis virus; Six-helix bundle; Anti-viral

1. Introduction

Severe acute respiratory syndrome (SARS) is an atypical pneumonia characterized by influenza-like symptoms including fever, cough, dyspnea and headache. The epidemic of 2002–2003 produced an overall mortality of approximately 10%, resulting in 774 deaths in 29 countries world-wide (Goldsmith et al., 2004; Holmes, 2005; Peiris et al., 2003b). The etiological agent of SARS (SARS-CoV) was quickly identified as belonging to the family Coronaviridae, a group of large enveloped RNA viruses exhibiting a broad host range and capable of causing respiratory, hepatic and enteric diseases (Lai and Holmes, 2001; Siddell, 1995). Initial phylogenetic analyses and sequence comparisons revealed significant differences between SARS-CoV and other CoVs, distinguishing it as a unique group (group 4), unrelated to previously characterized CoV groups 1–3 (Drosten et al., 2003; Ksiazek et al., 2003; Peiris et al., 2003a). More recent analyses, however, report that SARS-CoV more closely resembles group 2 CoV and should therefore be classified as a subgroup within group 2 (Goebelkenya et al., 2004; Magosinski et al., 2004; Song et al., 2005). Further phylogenetic
analyses and studies investigating the ancestral origins of SARS-CoV should yield a consensus regarding its proper grouping. Nonetheless, as animal reservoirs of SARS-CoV appear to exist, reemergence of this unique CoV is highly probable and therefore the threat of a new SARS outbreak remains a constant public health concern.

Like other enveloped viruses, CoVs enter target cells by inducing fusion between the viral and cellular membranes, a process mediated by the viral spike (S) glycoprotein (Gallaher and Buchmeier, 2001). The S1 subunit of the S protein mediates receptor binding (Cavanagh and Davis, 1986; Taguchi, 1995), while the S2 subunit is responsible for driving viral and target cell membrane fusion (Taguchi and Shimazaki, 2000). In the case of SARS-CoV, the S1 subunit binds to the mammalian receptor angiotensin-converting enzyme 2 (ACE2) (Huang et al., 2006; Li et al., 2003, 2005; Wang et al., 2004; Wong et al., 2004) and/or CD209L (Jeffers et al., 2004), initiating the entry process via a cathepsin-L-dependent pathway (Huang et al., 2006). Analysis of the murine hepatitis virus (MHV) and SARS-CoV S proteins (Li et al., 2005; Xu et al., 2004a,b,c) reveal common structural features shared with class I viral fusion proteins (Gallaher, 1996; Gallaher et al., 1989), including a hydrophobic fusion peptide (Sainz et al., 2005b), a pair of extended α helices (N-helix and C-helix) (Tripet et al., 2004), a loop domain separating the two α helices and a cluster of aromatic amino acids (Sainz et al., 2005a) proximal to a hydrophobic transmembrane anchoring domain. Class I viral fusion proteins mediate viral and target cell membrane fusion through a series of conformational changes involving insertion of a fusion peptide into the target cell membrane, trimerization and extension of the heptad repeat (HR) helices toward the target membrane and the subsequent formation of a six-helix coiled-coil bundle (Gallaher, 1987). In this structure, a trimer of HR1 helices forms a central coiled-coil surrounded by three HR2 helices in an anti-parallel mode (Xu et al., 2004b). The loop region is believed to act as a hinge, facilitating six-helix coiled-coil bundle formation and mediating membrane juxtaposition.

While current models of viral membrane fusion are hypothetical in most aspects, the importance of several of the structural/functional motifs of class I viral fusion proteins as drug development targets has been established. For example, analogs of the orthomyxovirus, paramyxovirus (Richardson et al., 1980) and HIV-1 fusion peptide domains (Gallaher et al., 1992; Owens et al., 1990; Silburn et al., 1998) block viral infection, presumably by forming inactive heteroaggregates. Likewise, peptides analogous to the HR regions of the viral fusion protein (Quereshi et al., 1990; Wild et al., 1992, 1993), paramyxovirus (Lambert et al., 1996; Young et al., 1999) or Ebola virus (EboV) (Watanabe et al., 2000) class I viral fusion proteins block virus infectivity by preventing the transition of the fusion protein into the six-helix bundle state. The anti-HIV-1 peptide drug Fuzeon™ (DP178, T-20 or enfuvirtide), which overlaps HR2 and the aromatic domain of gp41, was the first of a new class of fusion inhibitor antivirals to gain FDA approval (2003). This peptide has been shown to potently inhibit HIV-1 virion:cell fusion at very low concentrations (50% inhibition at 1.7 nM) in vitro (Wild et al., 1993). Likewise, in clinical trials, 100 mg/day of Fuzeon™ caused an ~100-fold reduction in plasma HIV-1 load of infected individuals (Kilby et al., 1998; Lalezari et al., 2003a,b). These results substantially validate the efficacy of this new class of antivirals and have greatly motivated the search for peptide fusion inhibitors designed to target other viruses, such as SARS-CoV (Gallaher and Garry, 2003; Kliger and Levanon, 2003).

To date, studies examining peptide fusion inhibitors of CoV have only examined the efficacy of peptides analogous to the HR regions of the viral fusion protein. Bosch et al. (2003) first demonstrated that a peptide analogous to the HR2 helix of the MHV S2 subunit could block viral entry at concentrations of 10–50 μM. Several other groups later showed that HR1 and/or HR2 peptides could likewise inhibit SARS-CoV entry and replication (Bosch et al., 2004; Liu et al., 2004; Yuan et al., 2004; Zhu et al., 2004). The antiviral capacity of these peptides is attributed to the inherent interactions between HR1 and HR2 (Tripet et al., 2004; Xu et al., 2004b,c). Peptides analogous to either one of the two HR regions are believed to directly inhibit endogenous HR1 and HR2 interactions, preventing formation of the six-helix bundle.

Although the HR analogs appear to be effective inhibitors of SARS-CoV entry in vitro, development of other peptide fusion inhibitors, based on non-HR regions of the viral fusion protein, has yet to be explored. Here we employed a novel approach to identify new peptide inhibitors of SARS-CoV. Using the Wimley and White (WW) interfacial hydrophobicity scale (IHS) (Wimley and White, 1996), we identified five regions within the SARS-CoV and MHV S2 subunit with a high propensity to interact with the lipid interface of membranes. These regions, spanning the entire S2 subunit, may play an important role in viral fusion protein:target cell membrane interactions and may therefore represent possible targets for therapeutic interference. Our results demonstrate that peptides analogous to these regions of high interfacial hydrophobicity are effective inhibitors of SARS-CoV infectivity. In particular, peptides analogous to the loop region and/or the N-terminal region of the S2 subunit potently inhibit CoV plaque formation by 70–90% at concentrations of 30 μM or less (~100 μg/ml). These findings provide an alternative approach to the development of viral peptide inhibitors, allowing for the identification of other possible therapeutic peptides outside of the HR regions of class I viral fusion proteins.
2.2. Cells and viruses

Vero E6 and L2 cells (American Type Culture Collection, Manassas, VA) were maintained in minimum essential medium (MEM) or Dulbecco modified Eagle medium (DMEM), respectively, and supplemented with 5% fetal bovine serum (FBS), penicillin G (100 U/ml), streptomycin (100 mg/ml) and 2 mM L-glutamine, at 37 °C in 5% CO₂. SARS-CoV strain Urbani was propagated in Vero E6 cells, and MHV strain A59 (ATCC, VR764) was propagated in L2 cells.

2.3. Viral plaque reduction assay

For plaque reduction assays, Vero E6 cells or L2 cells were seeded at a density of 1 x 10⁶ cells in each well of a 6-well plate 24 h prior to infection. Approximately 50 plaque forming units (PFU) of either SARS-CoV strain Urbani or MHV were pre-incubated with peptide or without peptide (diluent control) in serum-free MEM (SARS-CoV) or serum-free DMEM (MHV) for 1 h at 37 °C. Vero E6 or L2 cells were then infected with (1) peptide- or vehicle-treated SARS-CoV inoculum or (2) peptide- or vehicle-treated MHV inoculum, respectively. After 1 h adsorption, the inoculum was removed, cells were washed twice with 1 x phosphate buffered saline (PBS), and then overlaid with 10% FBS/MEM or 10% FBS/DMEM, both containing 0.5% Noble Agar (Sigma, Rockland, ME). L2 cells were fixed 2 days p.i., with 3.7% formalin for 2 h at room temperature and then stained with 1 x crystal violet to visualize plaques. Vero E6 cells were stained with neutral red 3 days p.i. and plaque numbers were determined 24 h later.

2.4. Cell viability assay

Cell viability was determined using the TACS™ MTT Assay (R&D Systems Inc., Minneapolis, CA) according to the manufacturer’s instructions. Briefly, Vero E6 cells or L2 cells were seeded at a density of 4 x 10⁵ cells in each well of a 96-well plate 24 h prior to treatment. Cells were subsequently treated with medium, diluent-control or 100 µg/ml (≈30µM) of peptide for 2 h prior to the addition of the tetrazolium compound MTT. Following incubation and subsequent addition of detergent, absorbance was read at 570 nm with a spectrophotometer.

2.5. CD spectroscopy

CD spectra were recorded on a Jasco J-810 spectropolarimeter (Jasco Inc., Easton, MD), using a 1 mm path length, 1 nm bandwidth, 16 s response time and a scan speed of 10 mm/min. All CD runs were performed at room temperature with 50µM peptide dissolved in 10 mM phosphate (PO₄) buffer at pH 7.0. Three successive scans between 190 and 250 nm were collected and the CD data are expressed as the mean residue ellipticity, derived from the formula $\Theta = \Theta_o (\text{deg} \times \text{cm}²)/\text{dmol}$. The latter is a highly conserved region among the Coronavirus family and is also present in class I viral fusion proteins of otherwise disparate RNA viruses, such as HIV-1 and EboV (Sainz et al., 2005a). The transmembrane domain of the S2 region also scored high on the WWIHS (Fig. 1A), and WW-II and WW-IV peptides correspond to the loop domain and the WW-V peptide corresponds to the aromatic domain.

2.6. Proteomics computational methods

Methods to derive general models of surface glycoproteins have been described previously (Gallaher et al., 1989). Domains with high interfacial hydrophobicity were identified with Membrane Protein eXplorer (MpeX; Stephen White laboratory; http://blanco.biomol.uci.edu/mpex). MpeX detection of membrane spanning sequences is based on experimentally determined hydrophobicity scales (White and Wimley, 1999; Wimley and White, 1996).

2.7. Statistics

Data are presented as the mean ± standard error of the means (S.E.M.). Data from peptide-treated groups were compared to vehicle-treated groups and significant differences were determined by one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test (GraphPad Prism©, San Diego, CA).

3. Results

3.1. Identification of peptides analogous to the CoV S2 subunit

Previous studies of potential peptide inhibitors of CoV have only examined the efficacy of peptides corresponding to the α helical regions (HR regions) of the S2 subunit (Bosch et al., 2004; Liu et al., 2004; Yuan et al., 2004; Zhu et al., 2004). Development of additional peptide fusion inhibitors, based on domains of the viral fusion protein other than the prominent α helices, has yet to be explored. We used a computational approach to identify regions of the SARS-CoV fusion protein that potentially interact with bilayer membranes (Winley and White, 1996). The WWIHS is an experimentally-determined algorithm that can be used to estimate the propensity of an amino acid sequence to interact with the lipid membrane interface (Winley and White, 1996). Five regions of high interfacial hydrophobicity within the SARS-CoV S2 region were identified using Membrane Protein eXplorer (MpeX) (http://blanco.biomol.uci.edu/mpex/), a computer program based on the WWIHS (Fig. 1A). WW-I and WW-II peptides correspond to the amino-terminus of the S2 region, predicted to contain the fusion peptide (Sainz et al., 2005b). WW-III and WW-IV peptides correspond to the loop domain and the WW-V peptide corresponds to the aromatic domain.

The latter is a highly conserved region among the Coronavirus family and is also present in class I viral fusion proteins of otherwise disparate RNA viruses, such as HIV-1 and EboV (Sainz et al., 2005a). The transmembrane domain of the S2 region also scored high on the WWIHS (Fig. 1A), but was not investigated as it is anchored within the viral membrane and not exposed during viral entry. Although the SARS-CoV S protein shares only 20–27% amino acid sequence similarity with the S protein of MHV (Rota et al., 2003), five analogously located peptides were identified as potential inhibitors based on domains of the viral fusion protein other than the prominent α helices, has yet to be explored. We used a computational approach to identify regions of the SARS-CoV fusion protein that potentially interact with bilayer membranes (Winley and White, 1996). The WWIHS is an experimentally-determined algorithm that can be used to estimate the propensity of an amino acid sequence to interact with the lipid membrane interface (Winley and White, 1996).
3.2. Identification of peptide inhibitors of CoV infectivity

Synthetic peptides corresponding to the sequences with significant WWIHS scores were synthesized (Table 1) and examined for their ability to inhibit either SARS-CoV plaque formation on Vero E6 cells, at peptide concentrations of \(\sim 30 \mu M\) (Fig. 2). SARSWw-I and SARSWw-II inhibited viral plaque formation by 58 and 39%, respectively. SARSWw-Va, however, did not show any inhibitory effect at this concentration. This peptide was of particular interest as it was modeled after the HIV-1 peptide inhibitor, Fuzeon\textsuperscript{TM} (Kilby et al., 1998) and corresponds to the C-terminus of the C-helix and the aromatic domain. Previous work from our laboratory has shown that the aromatic domain of both the SARS-CoV and MHV S2 subunit partitions into the membranes of lipid vesicles and are capable of compromising membrane integrity (Sainz et al., 2005a). We hypothesized that the inability of SARSWw-Va to inhibit SARS-CoV entry may be due to its propensity to partition into the lipid interface (Sainz et al., 2005a). A WW-V derivative with a five amino acid truncation of the aromatic domain (SARS WW-Vb, Table 1) was capable of inhibiting SARS-CoV plaque formation by 42% (Fig. 2A). Peptides corresponding to the loop region of the SARS-CoV fusion protein were the most effective at inhibiting SARS-CoV plaque formation. SARSWw-III and SARSWw-IV inhibited viral plaque formation by 90 and 83%, respectively (Fig. 2A). Shown in Fig. 2B–D is a representative photograph of SARS-CoV plaque formation in the presence of these two peptides. Consistent with the experimental results presented in Fig. 2A, SARS-CoV plaque efficiency was significantly inhibited in the presence of SARSWw-III and SARSWw-IV, as compared to vehicle-treated controls (Fig. 2C–D versus B).

To confirm that the observed anti-viral activity of the peptides tested was not a consequence of cellular cytotoxicity, a

Table 1

<table>
<thead>
<tr>
<th>Peptide*</th>
<th>Amino acid sequence</th>
<th>Net charge</th>
<th>Description</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARSWw-I</td>
<td>MIEKTPTLUYFGG-NPFSQQL\textsuperscript{a}</td>
<td>+2</td>
<td>N-terminal</td>
<td>770–788</td>
</tr>
<tr>
<td>SARSWw-II</td>
<td>ATAGWTFGAGAAL-QIPFAMQMY</td>
<td>0</td>
<td>N-terminal</td>
<td>864–886</td>
</tr>
<tr>
<td>SARSWw-III</td>
<td>GYHLMSFPQAAP-HGVVFLHVTW</td>
<td>+3</td>
<td>Loop</td>
<td>1028–1049</td>
</tr>
<tr>
<td>SARSWw-IV</td>
<td>GYFVQDDGE-WKFTGSSYYY</td>
<td>-3</td>
<td>Loop</td>
<td>1144–1162</td>
</tr>
<tr>
<td>SARSWw-Va</td>
<td>NEV AKNLNES-LIDLQELGKYE-QYIKWPWYVW</td>
<td>-2</td>
<td>HR2-Aromatic</td>
<td>1169–1194</td>
</tr>
<tr>
<td>SARSWw-Vb</td>
<td>NEV AKNLNES-LIDLQELGKYE-QYIKWPWYVW</td>
<td>-2</td>
<td>HR2-\Delta Aromatic</td>
<td>1169–1194</td>
</tr>
<tr>
<td>MHVww-III</td>
<td>GNHILSLVQNAP-YGLYFHPSQ</td>
<td>+2</td>
<td>Loop</td>
<td>1096–1117</td>
</tr>
<tr>
<td>MHVww-IV</td>
<td>GYFVQDDG-EWKFTGSSYYY</td>
<td>-3</td>
<td>Loop</td>
<td>1144–1162</td>
</tr>
</tbody>
</table>

\textsuperscript{a} The SARS-CoV (SARSww) and MHV (MHVww) peptides were synthesized based on the amino acid sequence determined from GenBank accession no. AY278741 (SARS-CoV strain Urbani) or AY700211 (MHV strain A59).

\textsuperscript{b} Amino acid change to tryptophan (W) is shown in underlined text.

The SARS-CoV (SARSww) and MHV (MHVww) peptides were synthesized based on the amino acid sequence determined from GenBank accession no. AY278741 (SARS-CoV strain Urbani) or AY700211 (MHV strain A59).
Fig. 2. Effect of peptides analogous to the viral S protein on SARS-CoV plaque formation. (A) Vero E6 were infected with virus pre-incubated for 1 h with 30 μM peptide. Cells were subsequently infected for 1 h, overlaid with medium containing 0.5% agarose and 4 days p.i., plaque numbers were determined. Percent inhibition in plaque formation was calculated as: 100 – ((no. plaques in peptide-treated/no. plaques in vehicle-treated) × 100). Significant reductions in plaque numbers relative to vehicle-treated cultures are denoted by a single asterisk (p < 0.05, one-way ANOVA and Tukey’s post hoc t-test). Vero E6 cells were infected with ∼40 PFU of SARS-CoV strain Urbani following a 1 h incubation with (B) vehicle or 30 μM of (C) SARSWW-III or (D) SARSWW-IV. Cells were stained with neutral red 3 days p.i., and cultures were photographed 24 h later. Arrows indicate representative SARS-CoV plaques. (E) SARS-CoV peptides do not affect cell viability. Vero E6 cells were treated for 2 h with 30 μM of SARS-CoV peptides. Cell viability was measured using the TACS™ MTT assay, and absorbance (OD570) is plotted for untreated (U), diluent-treated (D), and peptide-treated cultures.
Fig. 3. Peptides analogous to the loop region of the MHV S2 subunit inhibit viral plaque formation. L2 cells were infected with ∼40 PFU of MHV-A59 following a 1 h incubation with (A) vehicle or 30 μM of (B) MHVWW-IV. Cells were fixed and stained with crystal violet 2 days p.i., and cultures were photographed 24 h later. Arrows indicate representative MHV plaques.

MTT assay was performed as described in Section 2.4. Cells were treated with the tetrazolium compound MTT, which is reduced by metabolically active viable cells to purple formazan dye crystals. Absorbance (OD570) of solubilized crystals in peptide-treated or diluent-treated groups can be compared to untreated controls. Vero E6 cells treated with ∼30 μM of SARS-CoV peptides showed no difference in absorbance as compared to untreated cells. Likewise, diminished cell viability was not observed in cells treated with diluent control (Fig. 2E). These data indicate that the anti-viral capacity of the SARS-CoV peptides is not a result of cell cytotoxicity, which could directly affect CoV plaque formation.

3.3. Peptides analogous to the loop region of the MHV fusion protein inhibit MHV A59 plaque formation

The potent anti-viral effect observed with the SARS-CoV loop peptides prompted us to test whether peptides analogous to regions located within the loop of the MHV fusion protein had similar anti-viral efficacy. As illustrated in Fig. 1B, the MHV fusion protein also contains five regions of high interfacial hydrophobicity as determined by the WWIHS. Similar to the SARS-CoV fusion protein, two of these regions (MHVWW-III and MHVWW-IV) are located within the MHV S2 loop region. Synthetic peptides corresponding to these two regions (Table 1) were synthesized and examined for their ability to inhibit MHV strain A59 plaque formation on L2 cells at peptide concentrations of ∼30 μM. MHVWW-III and MHVWW-IV inhibited viral plaque formation by 22 and 98%, respectively (data not shown). Unlike the synthetic SARS-CoV loop peptides (SARSWW-III and SARSWW-IV), only one of the MHV loop peptides (MHVWW-IV) significantly inhibited MHV plaque formation on L2 cells. The potent anti-viral activity of MHVWW-IV is illustrated in Fig. 3. As compared to vehicle-treated controls, MHV plaque efficiency was significantly inhibited in the presence of MHVWW-IV (Fig. 3A versus B). Moreover, similar to the MTT assay results observed with the SARS-CoV peptides, the MHVWW-IV peptide was not cytotoxic at a concentration of 30 μM on L2 cells (data not shown).

3.4. Peptide-mediated inhibition of CoV plaque formation is dose-dependent

Based on the results presented above, we chose to further examine the inhibitory potential of SARSWW-III, SARSWW-IV and MHVWW-IV, as these peptides achieved levels of inhibition of greater than 70% at concentrations of ∼30 μM. Dose-response curves were generated for each peptide, where percent inhibition in viral plaque formation was plotted as function of peptide concentration (Fig. 4). The inhibition efficiency of these peptides was maintainable at low concentrations. The 50% inhibitory concentration (IC50) for both SARSWW-III and SARSWW-IV was approximately 2 μM (Fig. 4A and B). The other SARS-CoV peptides were statistically ineffective at concentrations less than 30 μM (data not shown). Similarly, the IC50 value for MHVWW-IV was 4 μM (Fig. 4C). In addition, the SARS-CoV loop peptides were ineffective inhibitors of MHV infectivity, suggesting some degree of sequence-specific inhibition (data not shown).

3.5. Circular dichroism analysis of the CoV loop peptide inhibitors

HR peptide inhibitors of SARS-CoV or MHV have α-helical structure and inhibit viral entry through coiled coil interactions (Bosch et al., 2003, 2004; Liu et al., 2004; Zhu et al., 2004). To assess the propensity of the loop peptides studied herein to adopt a defined secondary structure, peptides were examined by CD spectroscopy (Fig. 5). No distinct α-helical (minima at 208 and 222 nm) or β-sheet (minima at ∼218 nm) spectra were observed for any of the peptides in 10 mM PO4 buffer pH 7.0. Rather, spectra for all peptides in buffer showed single minima at or near 200 nm indicative of a random coil.

4. Discussion

SARSWW-III and SARSWW-IV have been independently identified as putative fusion peptides of the SARS-CoV S protein using biophysical approaches (Sainz et al., 2005b). Peptides
Fig. 4. Peptide-mediated inhibition of CoV plaque formation is dose dependent. Vero E6 cells were infected with SARS-CoV following a 1 h incubation with varying concentrations (0.125–60 μM) of (A) SARSWW-III or (B) SARSWW-IV. L2 cells were infected with MHV-A59 following 1 h incubation with varying concentrations (0.125–60 μM) of (C) MHVWW-IV. Percent inhibition in plaque formation was calculated as: 100 − ((no. plaques in peptide-treated/no. plaques in vehicle-treated) × 100). Significant reductions in plaque numbers relative to vehicle-treated cultures are denoted by a single asterisk (p < 0.05, one-way ANOVA and Tukey’s post hoc t-test).

Fig. 5. CoV inhibitory peptides do not assume a defined secondary structure. CD spectra (mean residue ellipticity θ) of the SARS-CoV peptides: (A) SARSWW-III and (B) SARSWW-IV, or the MHV peptide: (C) MHVWW-IV in 10 mM PO4 buffer pH 7.0 at room temperature.
tions and conformational changes that CoV S undergoes may be in a position different from other class I fusion proteins, e.g. the loop domain (WW-III or WW-IV), and the membrane interactions and conformational changes that CoV S undergoes may not follow the exact same mechanism.

SARSww-III, SARSww-IV and MHVww-IV, which correspond to sequences in the SARS-CoV or MHV loop domain, exhibited antiviral activity greater than the other peptides studied, inhibiting viral plaque formation with IC50 values of 2–4 μM (Figs. 2–4). Compounds that inhibit virus replication with IC50 in the low μM range can be considered promising lead compounds (Liu et al., 2004; Sia et al., 2002). Inhibition of plaque formation is likely to be the most stringent test of a viral inhibitor. Although different methods were used to quantify the antiviral effects, the IC50 concentrations are similar to or lower than peptide inhibitors corresponding to the HR regions of CoV previously identified. For example, the helical inhibitors described by Bosch et al. (2004) and Liu et al. (2004) exhibited IC50 in the range of 10–40 μM. Further studies are required to define the mechanisms by which the non-helical peptides (SARSWW-III, SARSWW-IV and MHVWW-IV) inhibit CoV infection. We hypothesize that these peptides may sterically hinder the loop, preventing either initial extension of the fusion protein, transition to the six-helix bundle state, or interaction of the S2 subunit with the cellular membrane. A recent study by York and Nunberg (2004) indicated that tryptophan residues in the loop domain of HIV-1 TM are critical for its interactions with the surface glycoprotein (SU), and therefore the inhibitory loop peptides may disrupt analogous S1/S2 region interactions. There is also currently conflicting evidence as to whether or not SARS-CoV S undergoes cleavage to S1 and S2 subunits (Bergeron et al., 2005; Wu et al., 2004).

MHV entry is not sensitive to lysosomotropic agents, and most current evidence indicates that MHV enters the cell through direct fusion with the plasma membrane (de Haan et al., 2004). Simmons et al. (2004) reported that inhibitors of endosomal acidification did impair entry of retroviral pseuodotype particles bearing SARS-CoV S. Therefore, the peptide inhibitors identified here may block S-mediated membrane fusion at different steps for SARS-CoV and MHV, at the plasma membrane, within endosomal compartments or both. Alternatively, some inhibitory peptides may interact directly with CoV virions. Further studies are required to elucidate the mechanisms by which SARS-CoV and MHV S peptides inhibit infectivity.

The CoV inhibitory loop peptides identified here did not have a propensity to adopt either an α-helical or β-sheet secondary structure, as determined by circular dichroism analysis (Fig. 5). Increasing the secondary structure, for example by the addition of alanine residues to promote α helix formation (Jayasinghe et al., 2001), may increase their antiviral activities. Studies are currently underway to evaluate this hypothesis, and to investigate other modifications to these CoV inhibitory peptides that may enhance their therapeutic potential.

5. Conclusions

Strategies for the treatment of SARS patients have included broad-spectrum antibiotics, glucocorticoids and ribavirin; however, the efficacy of these treatments is still unclear. Therefore, in order to develop better treatment strategies for future outbreaks, it is imperative to develop new therapeutics. In this study, we provide data to support the further investigation of peptide inhibitors as potential therapeutics for SARS-CoV infection. The immune response to SARS-CoV appears capable, in most individuals, of clearing the infection. Thus, therapeutics that inhibit viral infectivity and reduce SARS-CoV load may extend the window of time during which an effective immune response could arise.

Acknowledgments

This work was supported by the National Institutes of Health (AI054626, AI054238, RR018229, and CA08921; R.F.G.), (GM60000; W.C.W.) and (NO1 AI 25489; C.J.P.). Bruno Sainz is a recipient of a National Research Service Award from the NIAID (AI0543818) and Eric Mossel is a recipient of an Emerging and Re-emerging Diseases Fellowship from the NIAID (AI007536).

References

FDA notifications, 2003. FDA approves Fuzeon, the first fusion inhibitor. AIDS Alert 18(6), 78–79.


